News - Sunovion, Neurological

Filter

Current filters:

SunovionNeurological

Popular Filters

EU approval for Dainippon Sumitomo and Takeda’s Latuda

EU approval for Dainippon Sumitomo and Takeda’s Latuda

28-03-2014

Japanese drug majors Dainippon Sumitomo Pharma and Takeda Pharmaceutical have received European Commission…

Dainippon Sumitomo PharmaEuropeLatudaNeurologicalPharmaceuticalRegulationSunovionTakeda Pharmaceuticals

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

09-11-2013

The US Food and Drug Administration on Friday approved Sunovion Pharmaceutical’s (a subsidiary of Japanese…

AptiomDainippon Sumitomo PharmaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

Sunovion's eslicarbazepine successful in Ph III epilepsy studies

18-09-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

Dainippon Sumitomo PharmaeslicarbazepineNeurologicalPharmaceuticalResearchSunovion

Sunovion announces novel drug discovery partnership

14-08-2013

Sunovion Pharmaceuticals, a wholly-owned US subsidiary of Japanese drug major Dainippon Sumitomo Pharma…

AfraxisDainippon Sumitomo PharmaLicensingNeurologicalPharmaceuticalResearchSunovion

US FDA backs news indications for Latuda; grants Priority Review for Perjeta

02-07-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Sunovion files two sNDAs for Latuda with FDA

09-09-2012

Sunovion Pharmaceuticals, a US subsidiary of Japanese drug major Dainippon Sumitomo (TYO: 4506) has submitted…

Dainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

US patent settlements of Xopenex and Lidoderm

30-05-2012

US generics drug major Mylan (Nasdaq: MYL) has entered into a settlement agreement with Sunovion Pharmaceuticals,…

Dainippon Sumitomo PharmaEndo PharmaceuticalsGenericsLidodermMylan LaboratoriesNeurologicalNorth AmericaPatentsRespiratory and PulmonarySunovionWatson PharmaceuticalsXopenex

Sunovion’s Latuda non-inferior to AstraZeneca’s Seroquel XR in risk relapse for schizophrenia patients

30-10-2011

Sunovion Pharmaceuticals (SEPR: US) has announced results from a 12-month, double-blind extension study…

AstraZenecaLatudaNeurologicalPharmaceuticalResearchSeroquel XRSunovion

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top